BioCentury
ARTICLE | Company News

Axonyx to drop phenserine

November 8, 2005 2:52 AM UTC

AXYX said it will discontinue development of phenserine. The announcement follows three failed Phase III trials and one failed Phase IIb trial to treat Alzheimer's disease (AD) (see BioCentury Extra, Tuesday Sept. 20, 2005). AXYX said "positive signals" were seen in all the trials and that re-formulating the selective acetylcholinesterase (AChE) inhibitor may improve its efficacy profile. The company hopes to out-license the compound. ...